That includes proactive management of side effects, candid conversations about the long-term nature of treatment, infrastructure to identify and support patients at risk of stopping and addressing the cost barriers that make GLP-1 therapy unsustainable for many. These measures are especially important, Al-Aly noted, because the cardiovascular protection provided by GLP-1 medication builds slowly, but it erodes quickly
Secondly, it suppresses glucagon release , a hormone that raises blood glucose, thereby preventing excessive glucose production by the liver
Based on the function it does, it has been given different names
Lose 15% of your body weight with GLP-1s * Lose 15% of your body weight with GLP-1s * *In a 68-week placebo-controlled study of 1,961 obese and overweight non-diabetic adults with weight-related conditions, the treatment group receiving semaglutide experienced a mean body weight loss of 15%, compared to 2% of the placebo group